
BioNTech SE (BNTX) Stock Forecast & Price Target
BioNTech SE (BNTX) Analyst Ratings
Bulls say
BioNTech reported a robust financial position with approximately €16.7 billion in cash, cash equivalents, marketable securities, and trade receivables as of the end of Q3 2025, which supports its future growth and research initiatives. The company continues to make strides in its oncology pipeline, specifically with the ongoing evaluation of BNT323 in the Phase 3 DYNASTY-Breast02 trial, which is expected to contribute positively to its long-term performance. Additionally, BioNTech's development of an improved COVID-19 vaccine targeting multiple circulating sublineages demonstrates its commitment to innovation in infectious disease and strengthens its overall market position.
Bears say
The financial outlook for BioNTech is negatively impacted by several key risks, including the potential for negative clinical data from multiple drug candidates in its oncology pipeline and slower-than-anticipated market uptake for its products. Additionally, the company recorded a net loss per diluted share of €0.12 for the third quarter of 2025, with projections indicating a full-year net loss of €3.99, suggesting ongoing financial challenges. Furthermore, changing dynamics in the COVID-19 vaccine market, particularly due to a more restrictive regulatory environment in the U.S., may divert investor attention away from BioNTech's oncology initiatives.
This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.
BioNTech SE (BNTX) Analyst Forecast & Price Prediction
Start investing in BioNTech SE (BNTX)
Order type
Buy in
Order amount
Est. shares
0 shares